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Vaginal Contraceptives 

A Time for Reappraisal? 

Vaginal chemical contraceptives deserve a second look. 
Until the advent of oral contraceptives and IUDs in the 
1960s, creams, jellies, and suppositories were widely used, 
both with and without diaphragms and condoms. Then, 
vaginal contraceptive use declined. But in the last few 
years more effective foam preparations and more conven­
ient packaging have been developed. This product improve­
ment. coupled with the need for contraceptives that can be 
disseminated through nonmedical channels, suggests that 
vaginal contraceptives can still playa useful role in family 
planning programs. 
Vaginal chemical contraceptives, sometimes called 
spermicides or topical contraceptives, are made of rela­
tively inert base materials which physically block sperm 
plus active spermicidal agents which chemically immobilize 
or destroy sperm. One of the oldest forms of contraception, 
these preparations remain the only method of birth control 
used exclusively by a woman which does not require medi­
cal intervention or produce systemic effects. Vaginal con­
traceptives, like condoms, can be distributed in many 
ways-by smal'l stores, bazaars, door-to-door salesmen, 
vending machines, as well as in clinics or registered phar­
macies. The cost ranges from about $.02 (US) to $.45 (US) 
per application . 
The major drawback of vaginal methods is the relatively 
high failure rate. Compared with users of pills, IUDs, and 
even condoms, the users of vaginal contraceptives have a 
high incidence of accidental pregnancy. A US survey in 
1970 showed that, among couples practicing contraception 
for the purpose of either delaying or preventing pregnancy, 
31 percent of foam users experienced an unplanned preg­
nancy during the first 12 months of use as compared with 
6 percent of the pill users, 8 percent of the IUD users, 
17 percent of the condom users, and 33 percent of the 
rhythm users (135) (see Page H-39). 
Inconsistent Use a Problem 
The higher failure rates for methods like condoms, vaginal 
contraceptives, and rhythm are usually attributed to incon­
sistent use of the method rather than to failure of the 
method during use. As far as vaginal methods are con­
cerned, recent clinical studies suggest that the new prepa­
rations, particularly foams in aerosol, or pressurized, con­
tainers, can provide substantial protection if used regularly 
and correctly. Low pregnancy rates-i.e., below five per 100 
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woman-years of use-have been reported in several recent 
studies in the US (see Page H-45). 
There are other factors which limit wide-spread popularity 
and distribution of chemical contraceptives. As with all 
coitus-dependent methods, these preparations must be 
used almost immediately before intercourse, which inter­
rupts lovemaking. They must be inserted high into the 
vagina, which some women may be reluctant to do. They 
must be reinserted for repeated acts of intercourse . They 
may cause mild burning or irritation in some women. In 
the tropics, many of these preparations require special 
protection against heat and humidity. Other difficulties, 
including cost, transportation, and promotion, inhibit 
commercial distribution, especially in the rural areas of 
developing countries. 
If, however, the wide-spread medical skepticism about 
nonprescription methods of fertility control could be over­
come, these problems might also be solved. Certainly there 
are many parts of the world in which long standing folk 
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traditions support vaginal contraception, making this ap­
proach more acceptable at first than more modern tech­
niques. 
Useful Adjunct Methods 
No one today would advocate a family planning program 
emphasizing vaginal contraceptives as the primary method 
of fertility regulation. The question is whether these prepa­
rations fit into modern family planning programs in asso­
ciation with other methods and, if so, how. For example, 
vaginal contraceptives are sometimes recommended for 
use with the IUD during the first few months after insertion 
and with condoms during the most fertile time of the 
month. During lactation they can reinforce the contracep­
tive effect of breastfeeding. The lack of systemic reaction 
makes vaginal contraceptives suitable for women who have 
had side effects with oral contraceptives or IUDs. 
For young couples, vaginal methods can provide a simple 
introduction to contraception. At the other end of the age 
spectrum, women approaching menopause may find many 
of these products provide welcome vaginal lubrication as 
well as protection against a late pregnancy. At all ages 
women who have intercourse infrequently or women who 
have forgotten to take oral contraceptives regularly can 
find in vaginal contraceptives the occasional protection 
that is needed. 
Laboratory tests have shown that all vaginal contraceptives 
currently in use inhibit, in varying degrees, the growth of 
venereal disease organisms. Clinical studies now underway 
in the United States will determine whether in practice 
women using vaginal preparations can expect similar pro­
tection against VD. 
Most important from the point of view of current distribu­
tion facilities, vaginal contraceptives require no supervision 
by health personnel. Convenient packaging and simple 
graphic instructions are possible. In short, although vagi­
nal chemical preparations will certainly never replace oral 
contraceptives, sterilization, IUDs, and condoms, they can 
serve as a convenient back-up or alternative techniques. 
HISTORY 
The insertion of pastes, jellies, and various mixtures into 
the vagina in order to prevent conception is surely among 
the oldest and simplest methods of fertility control. As 
early as the 19th century B.C. the Egyptians were mixing 
honey, natron (sodium carbonate), and crocodile dung to 
form a vaginal contraceptive paste. In the 4th century 
B.C. Aristotle described the use of oil of cedar and frank­
incense in olive oil to block the cervical os. Peppermint 
juice mixed with honey was mentioned by Dioscarides in 
the 1 st century AD. Soranos, in his 2nd century classic 
Gynaecology, lists oil, honey, cedar gum, various fruit 
acids, and astringents like alum (76). Since environments 
that are either strongly acid or strongly alkaline are hostile 
to sperm, these early paste and chemical barriers probably 
did have some effect in limiting fertility. Salt in an 8 per­
cent solution, for example, is highly spermicidal. 
During the middle ages, rock salt and alum were frequently 
used as vaginal contraceptives. Indian writers in the 8th 
century described rock salt dipped in oil or honey as a con­
traceptive. Moslem physiCians in the 12th century recom­
mended suppositories or tampons containing rock salt, 
alum, or various fruit and herb juices. In Europe, a sponge 
moistened with diluted lemon juice and inserted into the 
vagina was cited in 1732 as an effective traditional 
fnethod (76). 
Coitus interruptus was widely practiced by the rural popu­
lation in Europe during the 18th and 19th centuries. As 
the rapid population growth which accompanied the In-
Fig. 1. Examples of Various Vaginal Contraceptives 
Top row (I-r): Antemin Cream (UK), Immolin Cream­
Jel (USA), Neo Sampoon Loop Foam Tablets (Japan), 
CCC Foam Tablets (Japan) 
Middle row (I-r); Emko Foam (USA), Delten Foam 
(USA). C-Film (Switzerland) 
Bottom row (I-r): Rendells Suppositories (UK). CCC 
Jelly (Japan), Gynomin Foaming Tablets (UK) 
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dustrial Revolution brought people to the cit ies, addit ional 
forms of contraception became accessible through the 
marketplace. The first commercial vaginal contraceptive 
was developed in 1885 by Walter Rendell , an English 
pharmacist. who prepared a suppos itory of soluble cocoa 
butter plu s quinine sulfate (7). (Quinine sulfate was re­
placed by hydroqu inone, a more potent spermicide, in 
1939 when it was discovered that the sperm icidal effect of 
quin ine su lfate was impaired by cocoa butter.) 
In the late 19th century, Annie Besant, t he Engli sh feminist 
leader who challenged laws prohibit ing the distribution of 
contracept ive information, was recommend ing a sponge 
soaked in Quin ine solution as a spermicida l vaginal bar­
rier. Several Dutch physicians in the late 1880s recom­
mended vagina l pl ugs made from soap. In 1895, W. P. 
Chunn in the United States suggested vaginal suppositories 
of coconut butter with boric acid, tann ic acid, or bichloride 
of mercury (76). Together w ith coitus interruptus, these 
vaginal methods, both homemade and commercial, w ere 
wide ly used before the development of latex rubber per­
mitted mass manufacture of cheap reliable condoms. 
Gradual recogn ition by the medi cal profession of the need 
for more reliab le forms of contracept ion spurred the devel­
opment of spermicidal je llies to be used with the dia­
phragm, invented in 1882 by Dr. W ilhelm Mensinga, and 
of cream bases for use either alone or with devices f itted by 
physicians. During t he 1920s and 1930s, numerous vagi­
nal suppositories and foaming tablets, many containing 
organo-metall ic compounds such as mercury, quin ine, 
chinosol, lactic acid, bori c acid, or burnt alum, were 
marketed in the United States and Europe. Because many 
physicians still refused to advise on or recommend birth 
contro l, vaginal contraceptives were sold primarily over the 
counter or by mail to consumers who were not protected by 
any official standards of safety or effectiveness. 
Today in many parts of the world homemade vagina l 
methods and simple spermi cides are still used. A tampon 
of cotton waste and mustard oil , for example, is popular 
in some regions of India, and douches of Coca-Cola, which 
is moderately acid and sperm icida l, have reportedly served 
the same purpose elsewhere (130,132). 
Surface Active Agents 
Compared w ith the volume of research required in recent 
years to develop steroidal contraceptives and IUDs, rela­
tively little study has been devoted to sperm icidal prepara­
tions. The modern trend has been toward vagi nal contra­
ceptives which combine a spermicidal agent of proven 
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Source: Ryder (135). 
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potency with a base material, or vehicle, as it is usually 
called, that will dissolve or disperse rapidly throughout the 
vagina and not irritate either the woman or her partner. 
At the same time, concern for toxicity and consumer safety 
has led some manufacturers to eliminate possibly haz­
ardous compounds, such as mercury and hydroquinones, 
from vaginal contraceptive products. Other substances 
which offer greater surface action and are less likely to be 
irritating, absorbed systemically, or harmful to a fetus have 
been substituted. 
A critical development in the early 1950s was the discovery 
that surface active agents (surfactants) such as nonyl­
phenoxy polyethoxy ethanol (nonoxynol-9) were effective 
spermicides. Unlike many of the earliest commercial formu­
lations, these are neither strongly acidic nor irritating to 
the vagina. They are increasingly used as the principal 
active ingredients in modern preparations (see Table 1). 
Application and Packaging 
Not only the ingredients themselves, but also the methods 
of application and packaging have been changed and im­
proved. In the early 1930s chemical suppositories and 
foaming tablets were inserted with the fingers. By the late 
1940s plastic applicator tubes with plungers were devel­
oped so that jellies could be inserted high in the vagina. 
When vaginal creams were introduced in the mid-1950s, 
the same applicator design was used. In recent years, 
single-dose tampon-shaped applicators, pre-filled at the 
factory and disposable after use, have been developed. 
In the late 1950s Joseph Sunnen, a St. Louis manufacturer 
and family planning enthusiast, developed Emko, a vaginal 
contraceptive foam containing nonoxynol-9 and ben­
zethonium chloride in a pressurized container. It was first 
marketed in 1961. Ortho Pharmaceuticals followed with 
Delfen contraceptive foam in 1963. 
The first foams came in glass bottles. Because foam could 
not be discharged directly into the vagina, single-dose 
applicators like those for creams and jellies were included. 
The applicator had to be filled just before coitus, sincefoam 
in the applicator lost its stability and became liquid after 
several hours. Most foams are still applied this way. 
In 1970 Emko introduced a single-dose applicator which 
the user can fill as much as one week in advance. The 
preparation is transferred from the can to the applicator as 
a liquid which, when applied, becomes foam in the vagina. 
Emko marketed a tampon-shaped container-applicator in 
1974. Factory-filled with six premeasured doses, it remains 
ready for use indefinitely and produces foam upon applica­
tion. The cost is high, about $1 .80 (US) for six applications, 
but it may be reduced in time. 
In Japan, the Eisai Company has developed small foam 
tablets with a new surface active agent, p-methanyl­
phenyl polyoxyethylene (8.8) ether, commonly called 
TS-88. The tablets are round with a hole in the center 
and look somewhat like white Life-Saver candies. They 
foam quickly and have a strong spermicidal effect. 
Water-soluble contraceptive fi 1m is the newest form of 
vaginal contraceptive. In Hungary several years ago 
Hotay developed a water-soluble plastic (polyvinyl alcohol) 
film as a base for the spermicide cetyl pyridinium bromide 
(CPB). He called this C-film (72). With nonoxynol-9 as the 
spermicide, C-film is now patented by USV Pharmaceutical 
Corporation and licensed for manufacture and sale by a 
British, a Swiss, and an Italian drug firm. Studies are being 
conducted in a number of European countries, and C-film 
is sold in Britain as an adjunct contraceptive method. 
MODE OF ACTION 
There are four basic types of chemical contraceptives used 
vaginally-creams, jellies, and pastes, which are squeezed 
from a tube; suppositories; foams, either in tablet form or 
pressurized containers; and soluble films (see Table 2). 
Each preparation has two components: a relatively inert 
carrier base or vehicle and an active spermicidal agent. All 
operate both mechanically, by forming a barrier to delay 
sperm progression, and biochemically, by immobilizing or 
destroying the sperm which have been blocked. 
Products squeezed from a tube include creams, jellies, 
and pastes. These diHer mainly in physical characteristics. 
Jellies a nd pastes are made from a variety of water-soluble 
bases, such as gelatin or gum tragacanth. The base material 
and spermicide incorporated within it liquify at body 
temperatures and disperse rapidly when they come in con­
tact with vaginal secretions. About four or five grams of 
jelly or paste are squeezed from the tube into a special 
applicator used to insert the product into the vagina. 
Creams, on the other hand, are made from water-insoluble 
fats, such as stearates or glycerin, which are compounded 
into an emulsion with the active spermicide dissolved in 
the aqueous portion (72). These preparations tend to re­
main wherever they are discharged into the vagina and 
not to disperse further. Thus correct positioning of the 
applicator is important. Creams provide protection within 
two to three minutes after application. Like jellies, they are 
packaged in tubes and require special applicators. 
Suppositories, sometimes called pessaries or vagitories, 
are either water-soluble gelatin-based or water-insoluble 
wax-based. They are designed to dissolve at body tempera­
ture, releasing active agents which, if placed high in the 
vaginal canal, will coat the cervix and vagina. For optimal 
effectiveness, most suppositories should be inserted about 
15 minutes before coitus. Spermicidal action then lasts 
about 20 minutes to one hour. Special packaging is re­
quired to prevent damage from heat and humidity. 
Foam products are available in tablet form or in pres­
surized containers. Foam tablets usually consist of tartaric 
acid and bicarbonate of soda with a powder base in which 
the spermicide is incorporated. In the presence of vaginal 
secretions carbon dioxide is released, generating foam. 
This takes from three to ten minutes depending on the 
product. Some manufacturers recommend moistening the 
tablet with a small amount of saliva or water before in­
serting it, so that foaming action is hastened. As the foam 
carrying the spermicide disperses over a broad surface area 
of the vagina, it produces a discernible amount of heat. No 
special applicator is needed, but moisture-proof packaging 
is required. 
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Jellies: 
CCC (Yamanouchi Pharmaceutical Co. Ltd., • 
Japan) 

Koromex-A (Holland-Rantos Co., Inc., USA) 
 • 
Lorophyn (Eaton Laboratories, Inc., USA) 

Orthogynol 2 (Ortho Pharmaceuticals, USA) 
 • 
Patentex (Patentex GmbH, GFR) • 
Preceptin (Ortho Pharmaceuticals, USA) • 
Ramses Contraceptive Vaginal Jelly (Schmid • • 
Laboratories, I nc., USA) 
Creams and Pastes: 
Antemin (Coates & Cooper Ltd., UK) • 
Conceptrol (Ortho Pharmaceuticals, USA) • 
Delfen Cream (Ortho Pharmaceuticals, USA) • 
Immolin (Schmid Laboratories, Inc., USA) 
Suppositories: 
Lorophyn (Eaton Laboratories, Inc., USA) 
Rendells (W.J. Rendell Ltd., UK) • 
Syn·A-gen (Dr. Herbrand KG, G FR) • 
Foaming tablets: 
Antibion (Patentex GmbH, GFR) • 
Gynomin (Coates & Cooper Ltd., UK) • • 
Neo Sampoon Loop (Eisai Co. Ltd ., Japan) • 
Semori (LuitpoldWerk, GFR) • 
Speton (Temmler-Werke, GFR) • • 
Syn-A-gen (Dr. Herbrand KG, GFR) • 
Aerosol foams: 
Delfen Foam (Ortho Pharmaceuticals, USA) • 
Emko Foam (The Emko Co., USA) 
Patentex (Patentex GmbH, GFR) • 
Soluble film: 
C·film (USV International, Belgium) • 
Isurface active agents may also possess bactericidal properties. 
2use with diaphragm recommended by manufacturer . 
SOU RCE: 	 Physician's Desk Reference , 1973; American Medical Association Bureau of Drugs; product labels and inserts; and personal 
communications with manufacturers. 
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Pressurized foam products, commonly called aerosol 
foams, consist of an o il and water emulsion stored under 
gas pressure. The liquefied gas propellant, w hen released, 
produces the foam . Depending on the type of container, the 
foam is either released into an applicator or, in newer de­
signs, discharged d irectly into the vagina, where the foam 
disperses w idely and provides immediate protection . 
Some foams can be inserted as much as one hour before 
coitus. 
Soluble films use polyvinyl alcohol and glycerine, sodium 
carboxymethyl cel lulose (CMC), or rice paper to carry 
sperm icides. C-f ilm is a four em square piece of trans­
parent, w ater-sol uble, paper-l ike plastic impregnated with 
nonoxyno l-9 . It requires no special applicator but is fo lded 
once and inserted into t he vagina by hand. C-fi lm should be 
placed in the vagi na 30 minutes before coitus (98) . 
Although Lagap SA. the Sw iss manufacturer, suggests in its 
package insert that C-film can also be placed over the peniS 
before coitus like a condom, this techn ique is not con­
sidered highly effective (1 ). 
Other films are made of different substances. For example, 
one Italia n contracept ive film uses r ice paper as its base; 
an Indian f ilm uses urea as the spermi cide although its 
potency is doubtful (70, 132). Before use soluble f i lm con­
traceptives must be protected against humidity and 
moisture. 
Biochemical Action 
The ingredients w hich determine a particular product's 
spermicidal or biochemical action may be predominately 
surface active, bactericidal, or hi gh ly acidic. Frequently 
two or more of these ingredients are comb ined in a s ingle 
product (see Table 1). 
Surface active agents are believed to attach themselves 
to the spermatozoa, inhibiting oxygen uptake and fructoly­
sis (the splitting up of fructose -sugar). Their primary 
action is in breaking down the sperm wall (15). The sim­
plest explanation, as Hardy and Wood put it, is that "they 
reduce the surface tension at the cell surface and thus in­
directly kill the spermatozoa by osmotic imbalance" (72). 
Among the most commonly used surface active agents are: 
nonylphenoxy polyethoxy ethanol (nonoxynol-9), p­
diisobutyl phenoxy polyethoxy ethanol, methoxy polyoxy­
ethylene glycol 550 laurate, and p-methanylphenyl poly­
oxyethylene (8.8) ether (TS-88) (see Table 1). 
The bactericidal agents used most frequently as spermi ­
cides are phenyl mercuric acetate (PMA), quinine com­
pounds, quartenary compounds, and ricinoleic acid and its 
compounds. They act by combining with the sulfur and 
hydrogen bonds within the spermatozoa, thus disrupting 
their metabolism (72). Actually the distinction between sur­
face active and bactericidal is not always clear since some 
bactericides act by altering the surface characteristics and 
potency of bacteria (13,17,37). Surfactants and bacteri­
cides together often have a synergistic effect, making the 
combined product a more effective spermicide than any 
one of the ingredients alone. Administered under direct 
medical supervision at frequent intervals or in concen­
trated form, some of these agents may also be effective 
aga inst common vaginal infections such as tr ichomoniasis 
or monol iasis, but t here is no evidence that they have a 
significant bacter icidal effect in normal contraceptive use. 
Highly acidic agents most likely to be used as sperm icides 
inc lude lactic acid, boric acid, tartaric and citr ic acids, 
and gum acacia , w hich w as a lso used in anci ent Greecefor 
blocking the cervix. Sometimes small quant ities of acidic 
agents are used in addition to other spermicida l ingredi ­
ents. 
Quality Control and Safety 
Spermic ides pose genuine problems in drug regu lat ion . 
Many products now in use were introduced before any 
nati on developed soph isticated regu latory authorit ies_ In 
Britain, for example, most products have a license " as of 
right " from the Committee for Safety of Medicines, which 
w ill review them according to a set timetab le. Although 
some tests for spermicidal effectiveness have been devel ­
oped, few tests have been made to evalu ate safety. Lack of 
reported adverse effects du r ing past use is the primary 
argument for the safety of exist ing formulations, but any 
new products, such as C-film, wi ll undoubtedly be subjected 
to much closer scruti ny. 
Biologically, a spermiCide could damage the genetic ma­
te ria l in the sperm head without killing the sperm and lead 
to abnormalities after fertilization , or it could be absorbed 
in m inute quantities and damage the woman or the devel­
oping fetus. The former is unproven and the latter has been 
investigated only w ith regard to certain mercury com ­
pounds. Although th ere are no studies or data showing that 
phenyl mercuric acetate (PMA) or any other compounds 
used in vaginal contraceptives have adversely affected 
human users, there are ample data proving the toxic ity and 
teratogenicity of other mercury compounds such as methyl 
mercury (110,118,156,176). Moreover, there is at least 
one Japanese study which showed fetal abnormalities in 
albino mice ranging from three to five times higher than in 
control groups when a portion of a contraceptive tablet 
containing PMA was introduced in the vagina on the 
seventh day of pregnancy. In addition to these fetal abnor­
malities, which involved primarily the central nervous sys­
tem, pathological changes suggestive of acute mercury 
poisoning were observed in the livers and kidneys of the 
mothers (113). To avoid this danger altogether and also to 
avoid the necessity of extensive testing to guarantee 
safety, a number of manufacturers have substituted sur­
face active agents for the organo-metallic compounds 
that were used initially. 
In the USA, the Food and Drug Administration (USFDA) 
has established an advisory panel, chaired by Dr. Elizabeth 
Connell, to review the safety, effectiveness, and labelling 
of over-the-counter drugs for human use including over­
the-counter contraceptives and other vaginal drug prod­
ucts (168). Although the panel has reached nofinal conclu­
sions, the following standards have been promulgated by 
the USFDA "to determine general recognition that a cate­
gory of OTC drugs is safe and effective ... " (1 67). 
(i) Safety means a low incidence of adverse reactions or 
significant side effects under adequate directions for use and 
warnings against unsafe use as well as low potential for 
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harm which may result from abuse under conditions of wide­
spread availability. Proof of safety shal l consist of adequate 
tests by methods reasonably applicable to show the drug is 
safe under the prescri bed, recommended, or suggested con­
ditions of use . This proof shall include results of significant 
human experience during marketing . General recognition of 
safety shall ordinarily be based upon published studies 
which may be corroborated by unpublished studies and 
other data. 
(ii) Effectiveness means a reasonable expectation that, in 
a significant proportion of the target population, the phar ­
macological effect of the drug, when used under adequate 
directions for use and warnings against unsafe use, will 
provide clinically significant relief of the type claimed. 
Proof of effectiveness shall consist of controlled clinical 
investigations, unless this requirement is waived on the 
basis of a showing that it is not reasonably applicable to the 
drug or essential to the validity of the investigation and that 
an alternative method of investigation is adequate to sub­
stantiate effect iveness. Investigations may be corroborated 
by partially controlled or uncontrolled studies, documented 
clinical studies by qualified experts, and reports of sig­
nificant human experience during marketing . Isolated case 
reports, random experience, and reports lacking the details 
which permit scientific evaluation will not be considered . 
General recognition of effectiveness shall ordinarily be 
based upon published studies which may be corroborated 
by unpublished studies and other data. 
(iii) The benefit-to-risk ratio of a drug shall be considered 
in determining safety and effectiveness . 
(iv) An aTC drug may combine two or more safe and effec­
tive active ingredients and may be generally recogn ized as 
safe and effective when each active ingredient ma kes a con ­
tr ibution to the claimed effect(s); w hen combining of the ac­
t ive ingredients does not decrease the safety or effectiveness 
of any of the individua l active ingredients; an d w hen the 
combination, when used under adequate directions for use 
and warnings against unsafe use, provides rational concur­
rent therapy for a significant proportion of the target pop­
ulation. 
Table 2-Major Characteristics of Various Types of Vaginal Chemical Contraceptives 
Type of 
Product 
Jelly and 
Paste 
I 
Cream I 
Suppesi­
tories 
Foaming 
tablets 
Aerosol 
foam 
Soluble 
film 
Frequentlv Used 

Base Materials 

Polyethylene 
glycol 
Gelatin 
Gu m tragacan th 
Stearates 

Stearic acid 

Glycerin 

Refined cocoa 
butter 

Stearines 

Soap 

Glycerin 

Bicarbona te 
of soda 
Polyethylene 
glycol 
Glycerin 
Tartaric acid 
Hydrocarbon 
and freon 
Polyethylene 
glycol 

Glycerin 

Polyvinyl alco· 
hoi 
Glycerine 
Rice paper 
Sodium car· 
boxymethyl 
icellulose (CMC) 
Frequently Used 

Act ive Ingred ients l 

Di·isobutylphen­
oxy poly­
ethoxy ethanol 
POlyoxyethy­
lenenonyl phenol 
Phenyl mercuric 
acetate (PMA) 
Nonoxynol-9 
Nonoxynol-9 
Polyethylene-
glycol of 
monoisoctyl 
phenol ether 
Polysaccharide­
polysuffuric 
acid ester 
TS·88 
Nonoxynol-9 
Chinosol 
Polysacchar ide· 
polysulfuric 
acid ester 
Chloramine 
Sodium dichlor­
osulphami­
dobenzoate 

Nonox ynol-9 
Benzethonium 
chloride 
Nonoxynol-9 
Packaging 
Tube 
Tube or single 
dose container 
Individual foil 
packages 
, 
Vial or indio 
vidual foil pack 
Aluminum or 
glass container 
Plas tic pouch 
contain ing 
cardboard ma tch· 
book-l i ke packet 
Mode of 

Application 

Plastic appl icator 
Plastic applicato r 
Manual insertion 
or with inserter 
Manual insertion 
Plastic appl icator, 
single or mul tiple 
dose 
I 
Manual insertion 
after folding 
Recommended 

minimum 

interval 

between appllca · 

tio n and co itus2 

2·3 minutes 
2-3 minutes 
3-15 minutes 
3-10 minutes 
None 
30 minutes 
Duration of 

Spermicidal 

Effectiven8$S2 

15 minutes· 
1 hour 
10 minutes ­
1 hour 
20 m inutes­
1 hour 
30 minutes· 
1 hour 
30 minutes· 
1 hour 
N.A . 
Isee also Table 1. 
21nterval between appl ication and coitus and duration of spermic idal effectiveness vary among products of the same type. Also, 
researchers' recommendations for the same product may vary . 
N.A. =Not Available. 
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(v) Labeling shall be clear and truthful in all respects and 
may not be false or mlsleading in any particular. It shall 
state the intended uses and results of the product; adequate 
directions for proper use; and warnings against unsafe use, 
side effects, and adverse reactions in such terms as to render 
them likely to be read and understood by the ordinary in­
dividual, including individuals of low comprehension, under 
customary conditions of purchase and use. 
(vi) A drug shall be permitted for OTe sale and use by the 
laity unless, because of its toxicity or other potential for 
harmful effect or because of the method or collateral 
measures necessary to its use, it may safely be sold and used 
only under the supervision of a practitioner licensed by law 
to administer such drugs. 
EFFECTIVENESS 
Determining the effectiveness of spermicidal preparations 
is a complex and sometimes controversial process. It begins 
in the laboratory and continues through animal, clinical, 
and even survey data to measure the actual use-effective­
ness of vaginal products as compared with other contracep­
tives. Even then there is disagreement about the best way 
to evaluate coitus-related methods since it is more often 
the user than the product which is responsible for failure. 
During the first stage of testing, the manufacturer usually 
undertakes in vitro tests for spermicidal potency, toxicity, 
local reactions, and possible carcinogenic properties. These 
are followed by comparable tests in animals, usually rab­
bits, since, in its sensitivity to spermicides, the rabbit 
vagina has proved more like the human vagina than those 
of other laboratory animals (46,152). After the spermi­
cide and base are combined, further tests measure the time 
required for dissolution, foaming, and product dispersal. 
Only then are clinical trials initiated, both with and without 
sexual activity. 
To measure in vitro the potency of the spermicidal ingredi­
ents,various special tests have been devised. Baker in the 
1930s developed one of the earliest tests, involving 48 dif­
ferent operations (7,8) . Other variations were developed 
by Brown and Gamble (20,59,60,61,62), Sander and 
Cramer (137), Millman (111), Davidson (36), Carruthers 
(24), and Harris (73). Many of these are now incorporated 
in the International Planned Parenthood Federation 
Agreed Test for Total Spermicidal Power (90,130). The 
IPPF test approves preparations if 1.0 ml of a 1 :11 solu­
tion immobilizes all sperm in 0.2 ml of semen within 40 
seconds after the semen and spermicide are mixed. Each 
product must pass the test three times using semen from 
three different donors or five times uSing semen from six 
different donors (90,130). 
There is considerable question, however, whether spermi­
cidal potency measured in vitro has any relationship to the 
clinical effectiveness of the preparation (2,102). Studies 
by Johnson and Masters, for example, suggest that the dis­
tribution and mechanical function of vaginal contracep­
tives can alter spermicidal potency. After observing simu­
lated coitus photographed intravaginally, they concluded 
that the manner in which the base material spreads in the 
vagina can determine whether the spermicidal agent, how­
ever potent in vitro, will function effectively in vivo . Best 
results were achieved with aerosol foams and creams. 
Using a point scoring method to evaluate contraceptive 
effectiveness at time periods ranging from a few seconds 
to eight hours after coitus, they found that only Delfen 
Cream (Ortho) and Emko Foam provided full protection 
after two injections of semen (87) (see Table 3). 
Sobrero's independent studies also confirm that, even 
though foam apparently disappears during coitus, the 
spermicide is well distributed. It forms a highly potent 
coating or film which sperm must traverse if they are to 
penetrate the cervical canal (151). 
Other formulations were less effective, Johnson and Mas­
ters found (86). Jellies did not disperse rapidly or thor­
oughly through the vagina, were excessively fluid, and 
sometimes caused irritation. Foam tablets varied widely 
in their dispersal capability, and some users complained of 
vaginal irritations such as burning and itching sensations. 
Suppositories often did not melt completely, causing an 
insufficient distribution of the contraceptive within the 
vagina (86). 
Measuring Effectiveness 
Even more difficult than measuring the efficacy of the 
vehicle and spermicide as separate components is the 
attempt to measure the efficacy of the composite product in 
actual use. With coitus-dependent contraceptives such as 
the condom, diaphragm, and vaginal chemical prepara­
tions, consistent use in each and every act of intercourse 
is more important than any other factor. Therefore, a dis­
tinction is sometimes made between theoretical (or physio­
logica I) effectiveness and use-effectiveness. Theoretical 
effectiveness measures the intrinsic capability of a specific 
contraceptive, when used correctly without human error or 
negligence, to prevent conception. Rates of theoretical 
effectiveness measure only "method failures" and are 
based on Iy upon pregnancies which occurred during regular 
Table 3-Comparison of Product Contraceptive 

Effectiveness by Point Scoring Method* 

Commercial 1st 2nd 3rd TotalContraceptive Insemi- Insemi- Insemi- PointsProduct nation nation nation 
Delfen Cream 180 180 148 508 
Emko Foam 180 180 130 490 
Lanesta Gel 170 180 130 480 
Lactikol Creme 176 144 100 420 
Lactikol Jelly 168 162 61 391 
Durafoam Tablets 159 72 3 234 
Lorophyn 
Suppositories 164 56 2 222 
Perfect 
performance score 180 180 180 540 
'One point is allotted for each vaginal specimen showing all 
sperm immobilized; six specimens were taken from each of 
30 subjects after each insemination. 
SOURCE : Johnson and Masters (87) . 
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Table 4-Effectiveness of Vaginal Chemical Contraceptives in Selected Major Studies Published Since 1960a 
Failure Rates 
Author and Date 
Refar­
ance 
N'um­
ber 
Brand 01 
Preparation 
Location 
01 Study 
Characteristics 
of Population 
Studied 
Number 
01 
Women 
Woman-
Months 
01 Use 
Average 
Duration 
01 Use 
(in Monthsl 
Number of 
Pregnancies 
(Pregnancies per 
100 Woman-Y earsl 
Method 
Method and User 
Failure Failure 
JELLIES 
Margolis, Cavanaugh, 104 Lan.sta-Gel USA Young clinic patients 259 3,250 12 .5 21 N.A . 7.75 
and Erns contacted monthly 
1962 
Kasabach 88 Koromex A USA Clinic patients 195 2,058 10.6 36 7.58 20.99 
1962 
Frank 54 Korome)( A USA Urban clinic patients; 684 6,594 9.6 127 N.A . 23.1 
1962 3 mo. contact 
Tietze. Pai, T aylar, 162 Koromex. Puena Young, married, low 462 4,987 10.8 150 N.A. 36.09 
IndGamble Lactikol, Rico income, rUfal; 
1961 Lorophyn, 3 mo. contact 
Ortho-Gynol, 
and Precept in 
CREAMS 
Rovinsky 134 Dellen USA Medically indigent 251 2,915 11 .6 22 3.70 9.06 
1964 clinic patients 
Tyler 164 Dellen USA Clinic patients, 508 6,783 13.3 35 .71 6.19 
1965 (full dosel in mid-1950s 
Dellen Same as above 164 2,748 16.8 9 .44 3.93 
(half dosel 
Dellen 
(hall dosel 
Combined sta tistics, 
6 investigators in 19505 
425 4,071 9.5 19 2.06 5.60 
SUPPOSITORIES 
God.ts 64 Syn-A-gen Belgium N.A . 56 1,344 24 2 N .A. 1.79 
1973 
FOAM TABLETS 
FuruSlwl et al 58 Neo Sampoon Japan Clinic patients, 124 1,058 8 .5 2 0 2.27 
1968 Loop most aged 25-35 
Ishihama .,d Inoue 82 Neo Sampoon Japan Farmers' wives, 587 8,955 15.3 24 0.67 3.22 
1972 Loop most aged 25-35 
Tyler 164 Dellen USA Combined statistics, 1590 11,096 7.0 133 4.22 14.38 
1965 11 investigators in 1950s 
Dingle and Tietze 39 Durofoam USA "Poorly motivated" 240 1,749 7.3 32 N.A. 21.96 
1963 clinic patients; 
3 mo . contact 
Tietza, Pai, Taylor, 162 Fomos Puerto Young, low income, 166 1,565 9.4 50 N .A. 38.34 
and Gamble Rico rural, married 
1961 
AEROSOL FOAMS 
Bushnell 21 Emko USA "Intelligent, 130 2,737 21 .1 4 0 1.75 
1965 motivated" 
Carpenter .nd 23 Emko USA "Low motivated 1778 17,200 9 .7 45 N.A. 3.14 
Martin and disadvantaged"; 
1970 3 mo. contact 
Bernstejn 14 Emko USA Mostly medically 2932 28,322 9.7 94 3.05 3.98 
1971 indigent; 
3 mo . contact 
Kleppinger 91 Dellen USA Clinic patients; 138 1,116 8.1 7 2.15 7.53 
1965 3 mo. contact 
Tietze and Lewit 160 Emko USA Hospital and 779 5,572 7.1 N .A. N.A. 28.3b 
1967 clin ic patients; 
' -3 mo. contact 
Paniagua. Vaillant. 127 Emko Puerto Low income, 142 1,723 12.1 42 N.A . 29.25 
end Gambia Rico urban, Catholic, 
1961 married ; 
contact each mo . 
SOLUBLE FILM 128 C·l ilm Europe N.A . 716 5,194 7.3 23 N.A . 5.31 
Pariser 
1974 
Egypt N.A . 91 1,638 18.0 10 N .A . 7.33 
N.A. = not available. 
aAlthough many studies of vaginal chemical contraceptives were conducted before 1960, changes of ingredients in some brands make the 

results of some early studies inapplicable to the products as now formulated. 

bAfter one year, as calculated by life table method. All other rates are calculated by the Pearl Formula . 
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contracept ive practice. Since the rates attributed to method 
failure in existing studies range from .4 (164) to 7.6 (88) 
per 100 woman-years, the theoretical effectiveness of 
vaginal contracept ives would appear to be fairly high (see 
Table 4). 
Use-effectiveness measures what actually happens in prac­
tice, that is, when careless or inconsistent use are con­
sidered together with "method failure." It is a more valid 
measure than theoretica l effectiveness. Use-effectiveness 
rates were originally calculated by the Pearl formula- the 
number of pregnancies per 1 00 woman-years of exposure­
and thus may be biased either by the relatively h igh failure 
rates of short-time users or by the relative ly low fa il ure 
rates of long-time users. A more sophisticated method, li fe 
table analysis, wh ich measures discontinuation rates over a 
specified length of time (extended use-effectiveness), is 
coming into wider use. 
Cli nica l trials show a great var iation in the effectiveness 
rates of vaginal contraceptives. These trials have taken 
place over a 40-year time period, using different types of 
vag inal contraceptives, different test populations, and dif­
ferent procedures for record keeping and fol low-up (11. 
41 , 42, 44, 45, 50-53, 63, 65-67, 74, 75, 92, 129, 139. 
155, 159, 163. 171. 174, 178, 179). Furthermore. studies of 
use-effectiveness were sometimes biased when irregu lar 
users or those w ho discon ti nued the method were excluded 
from the fina l calculations. Therefore, most of the results 
are not comparable w ith one another and certa inly do not 
provide conclusive evidence of the efficacy of vaginal 
methods or of one brand formulation as against another 
brand . 
Nevertheless. some points do emerge from recent, larger 
studies, which are summarized in Table 4. (Also see refs_ 
no. 10,26.55,103,108,109,1 16,122,124,140.150.) Preg­
nancy rates range from about two per 100 woman-years in 
several relat ively small clin ica l studies to a high of nearly 
40. The largest number of consistently low failure rates 
(less than five per 100 years of exposu re) are reported in 
rece nt research wi th Emko and Delfen foams in developed 
areas-either among private patients, or those attending 
Planned Parenthood cli nics who se lected foams volun­
tarily, or in other programs w ith continu ing follow-up. In 
several US studies, for example. women were introduced to 
the product by fami ly planning outreach w orkers of similar 
ethnic and social backgrounds who communicated to 
potential users their own conf idence in the product (14, 
21, 23,91 ,1 27, 164). 
Two studies, however, contradict the low rates other re­
searchers have found with foams. Tietze and Lewi t reported 
a pregnancy rate of 28.3 after 12 months for 779 US 
women using Emko foam. This ra te, calculated by the life 
table method, is lower than the pregnancy rate in the same 
study for women who used jellies or creams alone (36.8) 
but hi gher than that of women w ho used diaphragms with 
je lly (17.9) (160). In a Puerto Rica n study, Paniagua 
et 81 reported a failure rate w ith Emko foam of almost 30 
per 100 woman-years (127) (see Tab le 4). These rates are 
high in comparison to oral contraceptive or IUD preg­
nancy rates. 
Neo Sampoon Loop foam tablets, which are manufactured 
in Japan, resulted in pregnancy rates as low as 3.2 in a 
recently reported study including 587 Japanese farmers' 
wives (82). Other studies utilizing foam tablets, however, 
have reported failure rates as high as 38.3 per 100 woman­
years (see Table 4). 
A multi-center study of C-fi lm, sti ll unpublished. reported 
an overall pregnancy rate of 5.3 per 100 woman-years after 
5194 woman-months of use (128). On the other hand, 
C-f ilm failed a test by the British Family Planning Associa­
tion because nine pregnancies occurred among 45 women 
during 175 cycles, for a pregnancy rate of 62 per 100 
woman years. This is about the same as the rate which 
might be expected among women who use no contracep­
tion . Users found that the quick-dissolving film tended to 
adhere to sticky fingers and was therefore difficult to in­
sert (1 ,148). 
It has long been known that use-effectiveness is related to 
experience with the method and to the stage of family 
formation in which the couple find themselves. A recent US 
study by Professor Norman Ryder of Princeton based on 
survey data has provided further insight into the reasons 
for contracept ive failure. Regardless of the specific method 
used, contraceptors who were t rying to prevent further 
pregnanCies entirely were much more successful t han con­
traceptors tryi ng merely to delay or space pregnancies. Of 
those using foams to prevent births, 22 percent experi ­
enced an unwanted pregnancy compared with 36 percent 
of those seeking merely to delay birth s. But in the entire 
study 31 percent of those w ho used foams experienced un­
intended pregnancies, compared with 6 percent of those 
using pi lls, 8 percent using IUDs, 17 percent using con­
doms, 23 percent using diaphragms, 33 percent using 
rhythm, and 45 percent using a douche (135) (see Fig. 1). 
Over the last decade, vagina l contracept ives have 
been cri ticized or more often simply ignored by those 
in the family planning field because of the high fa i lure 
rates. On the one hand, many experts believe that theo­
ret ical and use-effect iveness should not be differentiated, 
that is, all fai lures should be considered method failures 
since intermittent use of a contraceptive method actually 
reflects dissatisfaction with it (70,99,157). 
On the other hand, some experts argue that those who 
choose vaginal methods today instead of more effective 
contraceptives may have ambivalent views about pre­
venting pregnancy. Therefore they may unconsciously 
choose and use a method carelessly, wi th resulting high 
pregnancy rates. Although contraceptive effectiveness is 
very important in some circumstances, in other cases, for 
example w here abortion is readily available, different fac­
tors may weigh more heavily in a couple's choice. Even if 
rel atively ineffective, a method which is easy to secure 
and use may double or triple the interval between births 
and thus meet individual or community needs more 
readily than a highly effective, sophisticated method 
which requires the supervision of trained medical per­
sonnel (136) . 
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Moreover, for t he infrequent user or for women who need 
temporary protection after IUD removal or omission of 
several pills or for women who prefer not to use orals or 
IUDs, vaginal contracept ives, especially foam, provide a 
reasonable a lternative comparable to condoms. Although 
not as effective as condoms, they do not require th~same 
degree of male cooperation as do condoms, nor do they 
diminish penile sensi tivity as condoms are sometimes 
alleged to do. 
.. 
\ USE AND DISTRIBUTION 
The International Planned Parenthood Directory of Con­
traceptives (71) lists contraceptives marketed th roughout 
the world, incl uding brand names, manufacturers, and dis­
t ributors of vaginal contraceptives . These include 65 
products in tubes (creams, je llies, or pastes), 35 supposi­
tories, 33 foam tab lets, and s ix pressu rized foams. Al­
though aerosol foams are probably the most effective of 
these, no more than five f irms manufacture them because 
of the large investment in equipment th at is necessary. In 
the USA and Britain the number of vaginal products on 
the market has decl ined steadily since the 1950s, wi th only 
about one third as many products listed in 1971 as two 
decades before (72). 
Assessing the actual use and distribution ofthese products 
is difficult (68). Since prescriptions are not required, 
women who select these methods are not likely to seek 
the advice of physicians, and, in t urn, phYSicians and 
family plann ing programs do not generally recommend or 
dispense vaginal contracepti ves unless orals, IUDs, or 
steri lization are contraindicated. On the w hole, use of 
vaginal methods is far less than that of orals, IUDs, 
ster ilization, or condoms, which have replaced vaginal 
methods in most developed countries. Use of aerosol foams 
and foam tablets, however, is increasing as compared to 
jellies and creams, and it may increase further in many 
countries if these products are more readi ly available and 
more vigorously promoted. 
An International Planned Parenthood Federation survey 
estimated that 1,041 ,500,000 doses of spermicides were 
distributed in 1971 in t he 73 countries w here IPPF affi li­
ates were able to provide informat ion (78). Two-th irds of 
these were in Western Europe . If 100 doses provide one 
year's protection for the average couple (177), the IPPF 
figure could mean that about 10.4 million w omen in those 
73 countries we re regular users of vaginal contraceptives. 
However, the use of vaginal cont racept ives is often 
irregular, and probably many more women use them, 
though not regularly. 
Estimates vary about the use of vaginal contraceptives in 
the USA and other developed countr ies. Accordi ng to one 
drug manufacturer's estimate about four million US women 
now use them (112). Another manufacturer has estimated 
there are more than two million current US users of foam 
(142). The 1970 US National Ferti lity Study placed the 
number of US users of contraceptive foam at about 1.5 
million in that year (135) . The study, based on a survey 
of over 5000 couples in which the wife was under 45, 
fou nd that use of foam had increased from 3.3 percent in 
1965 to 6.1 percent in 1970. By comparison, in 1973 
about 10 mi llion women in the US used oral contraceptives 
(131 ) and th ree to four million, IUDs (97,166). 
One point is clear. The use of vaginal contracept ives has 
declined substantial ly since oral contraceptives and IUDs 
were introduced in the early 1960s. In 1969 in Japan, 
where abortions were readily availabl e and orals and IUDs 
were not legal, about 9 percent of married women of repro­
ducti ve age used jellies or foam tablets (1 23). Elsewhere, 
use of vaginal contraception in recent years probably has 
not exceeded 5 or 10 percent of th e populat ion of repro ­
ductive age. In Melbourne, Australia, a retrospective 
survey of once-married women under 60 living w ith their 
husbands showed that the use of spermicides as the main 
method of fam ily planning decli ned f rom 20 percent in the 
1930s and 1940s to 2 to 3 percent in the late 1960s. 
From 1965 on, over 30 percent of these Melbournewomen 
were using orals (22). In Europe, a 1971 survey of family 
planning attitudes and practices ind icated that only 1 per­
cent of the married women in Great Britain w ere then using 
vaginal chem ical methods and even few er in Italy, Bel ­
gium, France, and West Germany (81). About 5 percent 
in Britain were using spermicides together with dia­
phragms or condoms (18). 
Promotion and Sales 
Before the 1960s, the major US manufacturers concen­
trated their sales effort on persuading phYSicians to recom­
mend specific vagi na I contraceptives for use together 
with diaphragms fi tted by phYSicians. Thus the most effec­
tive vagina l preparati ons were not promoted directly to 
the consumer market, but indirectly through the medical 
profeSSion. 
More recently, as t he diaphragm has been replaced by 
other methods and as publ ic discussion of family planning 
has made direct advertising and pharmacy display of non­
prescription contraceptives more acceptable, some manu­
facturers have undertaken more vigorous promot ion and 
distribution of vagina l contraceptives. In the USA, for 
example, the Emko Company, which produces no contra ­
ceptives except foam, has taken the lead in public adver­
tising, and now supplies 40 percent of the domestic foam 
market. The Ortho Pharmaceutical Corporation, on the 
The International Planned Parenthood Federation 
will provide upon request a full description of the 
Agreed Test of Spermicidal Power and a list of 
products which have passed the test . The IPPF 
Directory of Contraceptives (1971) is also avail­
able. Contact: 
The Medical Department 
International Planned Parenthood Federation 
18-20 Lower Regent Street 
London SW1 Y 4PW 
United Kingdom 
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other hand, which manufactures and distributes all types 
of vaginal and oral contraceptives as well as many other 
medical supplies, promotes its products primarily to phy­
sicians. During 1973, Ortho produced about 55 percent of 
the foam products sold in US pharmacies as well as about 
80 percent of the jellies and creams (80). 
In recent years vaginal contraceptives, particularly aerosol 
foam and cream products, have been advertised in women's 
magazines and in some general interest magazines. In order 
not to offend public sensitivities, however, most advertise­
ments describe the product in such vague terms that the 
message may not be conveyed clearly to the consumer. 
Moreover, some douches and other vaginal products are 
similarly advertised in such ambiguous terms that con­
sumers may think these products also have contraceptive 
value, even though they do not. In the USA many state 
laws prohibit contraceptive advertisements. US television 
accepts advertisements for vaginal sprays and vaginal 
douches which are used for cosmetic purposes but does not 
accept advertisements for vaginal contraceptives. 
There are fewer restrictions on contraceptive advertising 
in Europe and Japan, where advertisements appear in both 
newspapers and magazines, but not on television. In 
Sweden, foam is advertised widely, even at cinema per­
formances. 
Most developing countries accept family planning adver­
tisements which do not mention specific types of contra­
ceptives. India, Korea, Sri Lanka, Jamaica, and Kenya 
have permitted advertisements for condoms, but so far 
vaginal preparations have not been promoted in the same 
way. 
Sales of vaginal contraceptives are generally permitted 
through any retail outlet, although some US states and a 
few countries attempt to limit distribution to registered 
pharmacies. In certain European countries, such as Ger­
many, Sweden, Denmark, and the United Kingdom, vaginal 
contraceptives can be purchased in specialty shops which 
sell products associated with sex. Mail order sales are 
important in Germany and in some other countries. 
Sales in Developing Countries 
Several studies of contraceptive distribution through 
the commercial sector have been made in developing coun­
tries. In nine country surveys the Westi nghouse Popu lation 
Center interviewed fertile urban couples who had cash 
incomes. In Turkey, Pakistan, and Panama, users of foams/ 
creams or other products amounted to 4 percent of those 
interviewed. For Jamaica, the figure was 2 percent. Except 
in Pakistan, these users were all supplied through com­
mercial channels. In Iran, Korea, the Philippines, Thailand, 
and Venezuela, vaginal products were rarely used (172, 
173). 
A somewhat similar survey by Arthur D. Little Inc . (5) 
noted that vaginal contraceptives constituted "a minor 
volume of all contraceptives sold through commercial 
Table 5-Retail Prices of Selected Vaginal Contraceptive Products in Selected Countries, 1974 
Product Name 
Approximate Retail 
Price in uS$ 
(as of June 1974) 
Number of 
Applications 
Country of Sale Annual Sales or Number of Users 
Emko Foam $4.00 
$2.89 - $3.25 
30 
30 
UK, F inland, South Africa 
USA, Canada 
1 million users, USA & Canada 
20,000 users, UK 
40,000 users, Finland 
Gynomin foam tablets $ .75 
$1.10 
12 
12 
UK 
South Africa 
$50,000 (US), UK 
42,200 tubes, South Africa 
Duragel $ .37 + taxes 56 UK $14,100 (US), UK 
Conceptrol cream $2.63 10 UK 
Conceptrol cream premeasured $2.51 6 USA 
Neo Sampoon Loop tablets $2.11 
1.72 
1.10 
1.48 
1.20 
1.95 
1.80 
2.40 
1.90 
20 
20 
20 
20 
20 
20 
20 
20 
20 
Philippines 
Thailand 
Hong Kong 
Singapore 
South Vietnam 
Guatemala 
EI Salvador 
Dominican Republic 
Panama 
1,000,000 tubes, Japan 
530,000 tubes, Asia 
55,000 tubes, Africa and 
Middle East 
90,000 tubes, Latin America 
Peoples Republic Tablets $ .05 12 Peoples Republic of China N.A. 
Syn-A-gen/A-gen 53 
suppositories 
$1.85 - $2.72 6 Europe (5 countries) 
Africa (5 countries) 
Asia (11 cou ntries) 
Central America 
(10 countries) 
South America 
(2 cou ntries) 
5 million suppositories 
SOURCE: Data from manufacturers. Data on Peoples Republic Tablets from Ohneda (120). 
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channels" in Colombia, Iran, and the Philippines. "The 
reasons for the sma II vol ume," accordi ng to the study, were 
" lack of consumer demand, restriction on distribution to 
the drug network, and lack of product availability. The 
authors do not believe that drug firms are likely to in­
crease their efforts to promote these products because 
of lack of potential consumer demand for them" (5). 
Promotion, however, appears to increase consumer 
demand. In 1972 a four-month pilot project that provided 
pamphlets for pharmacists in Colombia to distribute with 
information on orals, condoms, and suppositories produced 
a 63 percent increase in suppository sales, an 81 percent 
increase in condom sales, and a 26 percent increase in 
orals sales. Even in drugstores which did not distribute the 
pamphlets, suppository sales increased by 39 percent (6). 
An analysis of contraceptive distribution in Nigeria, Ghana, 
Kenya, and Uganda during 1970 showed sales of 288,000 
vaginal foam tablets in Nigeria and 204,000 in Ghana, with 
smaller amounts sold in Uganda and Kenya . There were 
some tube cream sales in all four countries (16). Since sup­
positories have been used traditionally by the Yorubas in 
Nigeria as abortifacients and since in the minds of some 
men vaginal methods are less likely than pills or IUDs to 
encourage women to be unfaithful (125), a still larger 
market may exist in Africa for these products. 
Black noted that, "In West Africa, in particular, 'chemical 
sellers: or patent medicine dealers, felt this market was 
being held back by inadequate importation of products 
rather than by lack of demand." Manufacturers are "un­
willing to make any significant promotional investments in 
view of the threat to the markets from the increasing flood 
of subsidized contraceptives, as supplied through bilateral 
aid and distributed by family planning organizations" (16). 
Such evidence, although far from conclusive, suggests that 
a market may exist for vaginal products, but that these 
products so far have not been vigorously promoted. Nor 
have the most effective formulations been the most widely 
marketed. 
Table 6-Deliveries of Vaginal Chemical 

Contraceptives Financed by US Agency for 

International Development, by Fiscal Year and 

Continent, 1971-1974 1 

1971 1972 1973 1974 
I 
Latin America 2 
Foam 
Jelly 
Asia 
Foam 
Jelly 
Africa 
Foam 
Jelly 
TOTAL 
Foam 
Jelly 
58,945 
27,580 
10,153 
10,092 
119,260 
14,580 
188,358 
52,252 
64,684 
72,232 
4,394 
34,368 
127,794 
14,076 
196,872 
120,676 
49,983 
90,120 
4,664 
35,976 
100,470 
11,988 
155,117 
138,084 
47,931 
41,912 
406,975 
42,120 
40,258 
8,496 
495,164 
92,528 
lAlso, 4000 containers of vaginal tablets delivered to Africa in 

1974. Foams in number of 90 gram units or equivalent; jellies 

in number of tubes. 

21 ncludes Caribbean . 

SOURCE : US Agency for International Development, Com­

modity Reports System, December 1974. 

Table 7-New Acceptors of Vaginal Products in 11 

Government and/or Family Planning Association 

Programs, 1971 

Country Total New Acceptors 
New 
Acceptors 
of Vaginal 
Preparations 
Acceptors of 
Vaginal 
Preparations 
as Percent of 
Total 
Acceptors 
Bangladesh 127,051 54,389 43 
Barbados 3,265 1,081 33 
Pakistan 329,245 73,306 22 
Ghana 27,217 4,635 17 
Sierra Leone 701 99 14 
Jamaica 26,632 2,479 9 
Puerto Rico 44,660 4,033 9 
USA 1,263,837 93,375 7 
St. Lucia 2,390 146 6 
Ecuador 13,722 670 5 
German Federal 
RepUblic 2,100 97 5 
SOU RCE : Huber (78). 
Costs 
Retail prices vary considerably according to the type of 
vaginal product and the type of distribution outlet. In 
general, aerosol foams and premeasured doses of cream are 
the most expensive, tubes of cream are in the middle range, 
and jellies and foam tablets are the least expensive. Retail 
costs per application range from about $.02 (US) to $.45 
(US) (see Table 5 for selected prices). AJapanese manufac­
turer has reported that foam tablets are sold in the Peoples 
Republic of China for the equivalent of about one-half cent 
per tablet (120) . 
Bulk costs paid by international donor agencies are, of 
course, lower than retail prices, but in all instances the 
costs of vaginal contraceptives, like those of condoms, are 
increasing . In fiscal 1973 the US Agency for International 
Development (USAID) paid $.95 (US) for a 90 gram aerosol 
container of Emko with applicator. In 1974 the price was 
$1 .10 (US). Since 1.2 grams are required for protection, 
the per application cost is approximately one and one-half 
US cents. The cost to USAID for 50 grams of Delfen foam 
with applicator is $1 .30 (US). With slightly less than one 
gram needed for protection, the per application cost is 
approximately two US cents. UNICEF has recently pur­
chased Neo Sampoon Loop foam tablets at about $.65 (US) 
for 20 tablets, or about three US cents for each applica­
tion (121). These prices should be compared with the cur­
rent cost to USAID of approximately three US cents for a 
single condom (114) and approximately $.13 for a month's 
supply of oral contraceptives (38) when purchased in 
quantity. 
USAID Shipments 
At present the distribution of vaginal contraceptives 
through family planning programs is not substantial. 
USAID, which is the principal source of subsidized contra­
ceptive supplies, has not stressed vaginal contraceptives in 
its bulk purchasing because of a deliberate program deci­
sion to give first priority to the most effective methods. 
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For example, between fiscal years 1971 and 1974, 
USAID supplied about one mill ion 90·gram units or the 
equivalent of aerosol foams, approximately half of that 
in 1974 (see Table 6). USAID suppl ied about 400,000 
tubes of jelly over the same four-year period . 
Until 1974, the largest shipments of foam were consigned 
to Africa, w he re shortages of med ical personnel may have 
delayed the spread of IUDs and ora l contraceptives, bu t in 
1974 shipments to Asia increased a hundredfold. About 
300,000 units were sent to Bangladesh for its new family 
plann ing program. Pakistan, which stepped up its pro­
gram, rece ived about 100,000 units. 
Program Distribution 
The International Planned Parenthood Federation (lPPF) 
has gathered data on the choi ce of vaginal aerosol foam, 
foam tablets, je ll ies, and creams by patients In c li nics and 
other fami ly plann ing program facili t ies (78). An extensive 
study based on detailed questionna ires from 98 countries 
re vealed that in 1971 there were either no new acceptors or 
an unknown number of acceptors of vaginal methods re ­
ported in 65 country programs. These figures, of course, 
may be attr ibutable to program decis ions and to the non­
availability of vaginal preparat ions as well as to individual 
consumer choice. Of the 33 countries where government 
and lor pri vate fami ly planning programs did record new 
acceptors of vagina l preparations, on ly 11 showed 5 per­
cent or more accept ing these methods (see Table 7). 
IPPF-supported clinics have not experienced any great in­
crease in the use of je ll ies, creams or aerosol foams since 
1971. even though the use of ot her methods has grow n 
substant ially. Foam tablets, on the other hand, have be­
come more popular. In response to requests from local 
family planning aSSoCiations, IPPF supplied 16 times as 
many foam tablets in 1974 as in 1971 (see Table 8 ). This 
increase is caused in part by requests from new programs 
in the Phil ippines and in Indonesia , but it may also be the 
result of vigorous promotion by the Eisai Company of 
Japan of the new Neo Sampoon Loop foam tablets. To 
supply these requests, the IPPF purchases contraceptives 
directly from the manufacturers as well as obtaining them 
from USAID. 
Since most family planning administrators have not empha­
sized the use of vag inal contraceptives, t he present level 
of demand for these products, although not high, probably 
ref lects the continuing preference of some individuals and 
a few fami ly planning clin ics. The growing interest in non­
cl inical distr ibution by midwives, retai l outlets, bazaars, 
pedd lers, and the like- although so fa r focused pr imarily 
on condoms and pills- may eventually contribu te to wider 
use of self-administered vag ina l contraceptive methods. 
VENEREAL DISEASE PROPHYLAXIS 
If current research is successfu I, vaginal contraceptives 
may be shown to offer an additiona l benefit as a VD pro­
phylactic. Studi es now being carried out by Drs. Cut ler, 
Singh, and associates at the Universi ty of Pittsburgh are 
directed toward the identif ication of vaginal preparations 
with both contracepti ve and prophylactic prope rti es (13, 
17,30,31,32,33,34,95, 143, 144,145,146). 
Initial in vitro tests have compared 20 products which are 
now in use on the basi s of their effect on Neisseria gonor­
rhoeae and Treponema pa ll idum (syph ilis). They were 
Table a-Vaginal Chemical Contracept ives Provided by t he International Planned Parenthood Federation, 
by Calendar Year and Area, 1971·1974, and Scheduled Deliveries, 1975 (by number of containers) 
Product and Area Used 1971 
Used 
1972 
Used 
1973 
Est imated 
Usage 
1974 
To Be 
Delive red 
1975 
Total 
JELLI ES/CR EAMS 
Africa 
Asia 
leItin America 
and Caribbean 
TOTA L 
11 ,900 
21 ,083 
13,432 
46,415 
11,981 
26,936 
20,048 
58,965 
13,913 
30,242 
26,856 
71,011 
16,204a 
42,396 
32,020 
90,620 
7,530 
16,150 
41,984 
65,664 
61,528 
136,807 
134,340 
332,675 
FOAM TABLETS 
Africa 
Asia 
leIti n America 
and Caribbean 
TO TAL 
4,208 
3,931 
12,913 
21,052 
17,265 
19,341 
1,689b 
38,295 
20,751 
114,606 
2,540 
137,897 
23,856a 
286,820 
28,940 
339,616 
58,000 
53,300 
102,400 
213,700 
124,080 
477,998 
148,482 
750,560 
AEROSOL FOAMS 
Africa 
Asia 
Latin America 
and Caribbean 
TOTAL 
17,336 
17,661 
43,667 
78,664 
15,014 
12,311 c 
34,017 
61,342 
11,490 
54,639 
35,017 
101,146 
13,946" 
51 ,600 
36,000 
101,546 
7,384 
18,850 
59,246 
85,480 
65,170 
155,061 
207,947 
428,178 
aexclud ing Tunisia 
bexcl uding Trinidad and Tobago 
cexcluding Philippines and Sabah 
SOURCE : Internat io nal Planned Parenthood Federation, Report to Donors, September 1972,1973, and 1974 (82,83,84). 
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Table 9- Lowest Concentration of 20 Contraceptives Requ ired to Inhibit the Growth 
of N. Gonorrhoeae by Two Methods3 
Contraceptive 
Time-Exposure Method 
Concentration Growth after 
IParcent)b pH Exposure IMin .) 
1 5 10 
Plate-Dilution Method 
Concentration 
IPercen t) pH
c Growthd 
Cartane Vagina l Jelly 
Contra Creme 
Contra Foam 
Cooper Creme 
Delfen Cream 
Delfan Foa m 
Em ko Concentrate 
Emko Concent rate +A 
Emko Co ncentrate +8 
Emko Co ncent rate + Spermicide 
Emko Foam 
Im molin Vaginal 
Koromex A Vaginal Jelly 
Lanesta Gel 
Lorophyn Suppositories 
Miiex Crescent 
Ortho Creme 
Orthogynol Jelly 
Preceptin Gel 
Ramslls Vaginal 
10 4.6 + - -
50 6.9 + ± -
10 7.5 ± - -
1 6.7 - - -
20 5.2 + + + 
50 4.9 - - -
50 7.4 - - -
50 7.1 - - -
50 7.2 - - -
20 7.0 + + -
10 7.3 - - -
50 4.9 - - -
10 6.0 + - -
10 5.6 + - -
10 5.7 + - -
10 5.7 - - -
1 6.2 + - -
10 5.5 + - -
1 5.6 - - -
50 6.7 + + -
10 7.5 -
10 7.5 -
10 7.5 -
10 7.6 -
10 7.6 -
20 7.6 -
20 7.5 -
20 7.2 -
20 7.2 -
20 7.3 -
10 7.4 -
10 7.5 -
50 7.5 -
10 7.5 -
10 7.5 -
10 7.5 -
1 7.4 -
10 7.4 -
1 7.4 -
50 7.5 -
aBacterial suspension for these experiments contained about 106 CFU per 0.1 ml, the inoculated Thayer-Martin selective medium plates 

were incubated at 37°C. in CO 2 incubator. 

bOnly 50,20, 10, and 1 percent dilutions in physiological saline solution were tested. 

cpH of media after adding the contraceptive at different concentrations. 

dResults from duplicate plates. 

SOURCE: Singh, Cutler, and Utidjian (145). 
analyzed according to the length of time required to kill 
the VD organisms and the minimum concentration that was 
effective against them. 
In 1-,5-, and 1 O-minute time exposure tests three contra­
ceptives-Cooper Creme, Ortho Creme, and Preceptin Gel­
at a 1 percent dilution inhibited the growth of N. gonor­
rhoeae bacteria. Eight of the contraceptives were effective 
at 10 percent concentration. In a plate-dilution test, Ortho 
Creme and Preceptin Gel were effective at a 1 percent 
concentration, and eleven others, at a 10 percent concen­
tration (see Table 9) (145). 
In tests of the effectiveness of various vaginal contracep­
tive products against syphilis, an Emko concentrate and 
Ortho Creme at a 1 percent concentration immobilized T. 
pallidum, the spirochete responsible for syphilis, within 1 
to 1.5 minutes; 12 preparations were effective at a 10 per­
cent concentration, three at 20 percent, and two at 50 per­
cent (see Table 10) (145). 
Preliminary results of these tests have been encouraging 
and further in vitro and in vivo tests are planned. Progress 
in this area is especially important for several reasons: 
public health measures have had limited success in con­
trolling the spread of venereal disease (147,175); gonor­
rhea is becoming more resistant to penicillin therapy 
(101,147,153,154); syphilis, although not resistant to 
penicillin, is infecting more and more people, an in­
creasing proportion of whom react advetsely to the drug. 
A vaginal preparation which offers both contraception 
and VD prophylaxis might be a major step in preventing 
the spread of VD. Such an agent would be the first female 
contraceptive method to offer the kind of dual protection, 
even to a limited degree, against both venereal disease 
and pregnancy which has long been provided by the 
condom (35). 
Table 10-Dilutions of Contraceptives Required 

to Immobilize T. Pallidum Suspension 

within 1 to 1.5 Minutes 

Concentration Number ofName of Contraceptive 
Ipercent) Contraceptives 
Emko Concentrate +8, 1 2 
Ortho Cream 
Certane Vaginal Jelly, Contra 12 
Foam, Cooper Creme, 
Delfen Cream, Delfen 
Foam, Emko Concen­
trate, Emko Concentrate 
+A, Finesse, Immolin 
Vaginal Cream-Jel, 
Lorophyn Suppositories, 
Orthogynol Jelly, 
Preceptin Gel 
Contra Creme, Lanesta Gel, 
10 
20 3 
Ramses Vaginal Jelly 
Koromex A Vaginal Jelly, 2 
Milex, Crescent Jelly 
50 
SOURCE: Singh, Cutler, and Utidjian 1145). 
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